Developing a new generation of vaccine technologies

Learn More

Current Projects

A macro rendering of the SARS-CoV-2 virus

Hexamer’s most exciting opportunity yet.
Read how our innovative vaccine technology is being used to build a variety of vaccines.

  • By using our platform (instead of mRNA) to attach targets for cancers like Triple Negative Breast cancer and Glioblastoma, researchers are able to quickly validate vaccines using publicly available target information. There are additional opportunities for cancer treatments and infectious disease prevention using the technology. Contact Robert Bogden for more details.

  • We have licensed access to the platform to several companies developing vaccines for use in mammals like: swine, cattle, sheep, horses and companion animals. The first products are scheduled to be released in 2027. There are additional opportunities for disease prevention and optimizing animal production using the technology. Contact Robert Bogden for more details.

Latest Press Releases

Featured
Hexamer Therapeutics Receives USAMRDC Funding to Develop Breakthrough Vaccine Technology for Global Health Security

Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.

Read more →
Complete Neutralization of Live COVID-19 Virus Via Revolutionary Patented Vaccine Technology

Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised. IVT will manage and optimize vaccine manufacturing and distribution in partnership with global leaders in peptide manufacturing.

Read more →

As innovators, we are focused on creating ways of solving health problems every single day.

A scientist wearing safety goggles examining material using tweasers

WHO WE ARE

A Passionate Team of Scientists on a Mission

We are privately funded for Therapeutic Cancer and Infectious Disease Vaccine development with the vision of rapid vaccine deployment from "disease target on a computer screen" to "active vaccine." Our customized vaccines will empower the patient's immune system to fight heterogeneous metastatic cancer tumors or convey disease protection.

A scientist wearing safety goggles adjusting lab equipment

WHAT WE DO

Utilizing Advanced Technologies to Redefine Medicine

Our modular, scalable, room temperature vaccine platform is ideally suited to address many challenges presented by endemic and pandemic threats. We are focused on delivering safe, robust, easy to distribute and inexpensive vaccines for infectious diseases and cancer treatments.

World Class Team of Founders

  • Dr. Collin Collins, PhD

    Dr. Collin Collins, PhD

    Chief Scientific Officer (CSO)


    Senior Scientist, Vancouver Prostate Centre & UBC Professor, BC Canada. A world leader in cancer research with +300 peer-reviewed publications and known for co-inventing Next-Gen DNA sequencing technology. Previous positions include Lawrence Livermore National Laboratory, Lawrence Berkeley National Laboratory and the UCSF Comprehensive Cancer Center.​


    LinkedIn | GoogleScholar

  • Mr. Robert Bogden

    Mr. Robert Bogden

    Chief Executive Officer (CEO)


    Founded, ran, and successfully bootstrap financed a genomics company for +30 years with +$40M USD in revenues. Recognized by Deloitte and Touche as the 15th fastest growing technology company in Washington State and #442 in North America. On the team that discovered the BRCA-1 Breast Cancer gene in 1994. Has +20 years experience running a vaccine company inventing and deploying vaccines for agriculturally important animals.


    LinkedIn | GoogleScholar | ResearchGate

  • Dr. Keith Miller PhD

    Dr. Keith Miller PhD

    Chief Technology Officer (CTO)


    Over 30 years of biochemistry and immunology experience. Made a career of inventing hapten carrier vaccines for animals and humans. Specializes in protein design and engineering especially relating to vaccine immunogenicity and effector functions. Previous positions include a Senior Research Scientist for 12 years at Pacific Northwest National Laboratory developing novel fluorescent-based protein detection reagents for national security applications, and single-chain antibodies for the detection of a variety of cancers.


    LinkedIn | GoogleScholar

Vials of bottles labeled "VACCINE COVID-19"

OUR IMPACT

Benefiting the Community - Locally & Globally

Scientists working with our 100% peptide based vaccine platform can quickly adapt their vaccines to address new emerging bio-threats like: swine flu, avian flu, seasonal flu, new strains of SARS-CoV-2, Zika virus, and Ebola. Threats can be addressed in a few weeks time, with scale up time for global deployment measured in months.